JP2020502066A5 - - Google Patents

Download PDF

Info

Publication number
JP2020502066A5
JP2020502066A5 JP2019527417A JP2019527417A JP2020502066A5 JP 2020502066 A5 JP2020502066 A5 JP 2020502066A5 JP 2019527417 A JP2019527417 A JP 2019527417A JP 2019527417 A JP2019527417 A JP 2019527417A JP 2020502066 A5 JP2020502066 A5 JP 2020502066A5
Authority
JP
Japan
Prior art keywords
cancer
carcinoma
pharmaceutical composition
disease
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2019527417A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020502066A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/062643 external-priority patent/WO2018094362A1/en
Publication of JP2020502066A publication Critical patent/JP2020502066A/ja
Publication of JP2020502066A5 publication Critical patent/JP2020502066A5/ja
Withdrawn legal-status Critical Current

Links

JP2019527417A 2016-11-21 2017-11-20 キナーゼ阻害剤としての複素環式化合物 Withdrawn JP2020502066A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662424978P 2016-11-21 2016-11-21
US62/424,978 2016-11-21
PCT/US2017/062643 WO2018094362A1 (en) 2016-11-21 2017-11-20 Heterocyclic compounds as kinase inhibitors

Publications (2)

Publication Number Publication Date
JP2020502066A JP2020502066A (ja) 2020-01-23
JP2020502066A5 true JP2020502066A5 (enExample) 2021-01-07

Family

ID=62145877

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019527417A Withdrawn JP2020502066A (ja) 2016-11-21 2017-11-20 キナーゼ阻害剤としての複素環式化合物

Country Status (8)

Country Link
US (1) US10807966B2 (enExample)
EP (1) EP3541806A4 (enExample)
JP (1) JP2020502066A (enExample)
CN (1) CN110382481A (enExample)
AU (1) AU2017362571A1 (enExample)
CA (1) CA3082254A1 (enExample)
IL (1) IL266789A (enExample)
WO (1) WO2018094362A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114728926A (zh) * 2019-11-15 2022-07-08 武汉朗来科技发展有限公司 一种rock抑制剂及其制备方法和用途
CN112979675B (zh) * 2019-12-12 2023-12-19 维眸生物科技(上海)有限公司 一种小分子含硫杂环化合物
CN113121443B (zh) * 2019-12-31 2024-07-09 财团法人工业技术研究院 β-氨基酸衍生物、含其之激酶抑制剂与医药组合物以及其用途
KR102758256B1 (ko) * 2019-12-31 2025-01-21 인더스트리얼 테크놀로지 리서치 인스티튜트 β-아미노산 유도체, 키나아제 억제제 및 이를 함유하는 약학 조성물
EP4192828A1 (en) 2020-08-04 2023-06-14 Nura Bio, Inc. Substituted pyridine derivatives as sarm1 inhibitors
WO2022060812A1 (en) 2020-09-16 2022-03-24 Nura Bio, Inc. Substituted pyridine derivatives as sarm1 inhibitors
US20240285621A1 (en) * 2020-09-23 2024-08-29 Nerviano Medical Sciences S.R.L. Pyrazolyl-pyrimidine derivatives as kinase inhibitors
KR20240041987A (ko) 2021-07-28 2024-04-01 누라 바이오, 인크. Sarm1 억제제로서 치환된 피리딘 유도체
TW202500130A (zh) * 2023-05-09 2025-01-01 美商安進公司 用作15-前列腺素脫氫酶調節劑之5,6-稠合和6,6-稠合的雙環醇和醚及組成物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0218625D0 (en) * 2002-08-10 2002-09-18 Astex Technology Ltd Pharmaceutical compounds
US20050090529A1 (en) * 2003-07-31 2005-04-28 Pfizer Inc 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
BRPI0713187A2 (pt) * 2006-07-20 2012-10-16 Mehmet Kahraman método de inibir rho-quinase, método de tratamento de doença mediada por rho-quinase, composto e composição farmacêutica
EP2234487A4 (en) 2007-12-19 2011-09-07 Scripps Research Inst ANILIDES AND ANALOGUES AS INHIBITORS OF RHO KINASE
US20100093714A1 (en) * 2008-10-13 2010-04-15 Devraj Chakravarty AMIDES OF THIENO[2,3-d]PYRIMIDINE AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS
US20130129677A1 (en) 2009-02-27 2013-05-23 Siga Technologies, Inc. Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections
US9221808B2 (en) * 2010-04-16 2015-12-29 H. Lee Moffitt Cancer Center And Research Institute, Inc. Pyridylthiazole-based ureas as inhibitors of Rho associated protein kinase (ROCK) and methods of use
US8697911B2 (en) 2010-07-07 2014-04-15 Boehringer Ingelheim International Gmbh Rho kinase inhibitors
SG10202010119TA (en) * 2010-11-15 2020-11-27 Abbvie Inc NAMPT And Rock Inhibitors
US9284298B2 (en) * 2011-04-11 2016-03-15 Nerviano Medical Sciences S.R.L. Pyrazolyl-pyrimidine derivatives as kinase inhibitors
AU2016264220A1 (en) 2015-05-18 2018-01-04 Translational Drug Development Llc Heterocyclic compounds as kinase inhibitors

Similar Documents

Publication Publication Date Title
CN110582489A (zh) Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途
JP2018515623A5 (enExample)
JP2019514863A5 (enExample)
CN115803325A (zh) 一种egfr抑制剂及其制备方法和应用
JP2022507267A5 (enExample)
KR101501785B1 (ko) 과증식성 장애 및 혈관형성과 관련된 질환 치료에 유용한 치환된 2,3-디히드로이미다조[1,2-c]퀴나졸린 유도체
CN100575345C (zh) 对2型大麻素受体具有结合活性的吡啶酮衍生物
US20240246915A1 (en) Aminonaphthoquinone compounds and pharmaceutical composition for blocking ubiquitination-proteasome system in diseases
ES2988336T3 (es) Un agente antineoplásico 1-((4-(4-fluoro-2-metil-1H-indol-5-iloxi)-6-metoxiquinolin-7-iloxi)metil)ciclopropanamina, su forma cristalina y sus sales
TWI351956B (en) 6-alkenyl and 6-phenylalkyl substituted 2-quinolin
CN106660974A (zh) 含氨磺酰基的1,2,5‑噁二唑类衍生物、其制备方法及其在医药上的应用
JP2013544847A5 (enExample)
JP2018516917A5 (enExample)
JP2009535335A5 (enExample)
US10745350B2 (en) Compounds and pharmaceutical composition associated with ubiquitination-proteasome system
JP2020504716A5 (enExample)
EP1558252A4 (en) SUBSTITUTED FURO 2,3-B | PYRIDINE DERIVATIVES
JP2014502601A (ja) 置換6,6−縮合窒素複素環化合物及びその使用
TW201124395A (en) Therapeutic compounds and related methods of use
JP2015518899A5 (enExample)
JP2017532360A5 (enExample)
JP2017526731A5 (enExample)
PH12017501989B1 (en) Heteroaryl derivative or pharmaceutically acceptable salt thereof, preparation method therefor, and pharmaceutical composition for preventing or treating diseases associated with pi3 kinases, containing same as active ingredient
JP2020511468A5 (enExample)
JP2020506884A5 (enExample)